2.

PFS and OS of first-line trastuzumab treatment (N=85)

Survival	Treatment effi cacy
PFS, progression-free survival; OS, overall survival; ABC, advanced breast cancer.
PFS of fi rst-line trastuzumab treatment in ABC
Median (range), month	10 (2-59)
n (%)
≥median	41 (48.24)
<median	44 (51.76)
OS (time from fi rst-line trastuzumab treatment in ABC)
Median (range), month	16 (2-70)
n (%)
≥median	35 (41.18)
<median	50 (58.82)
OS (time from the date of advanced disease)
Median (range), month	22 (2-116)
n (%)
≥median	43 (50.59)
<median	42 (49.41)
OS (time from diagnosed breast cancer initially)
Median (range), month	50 (8-352)
n (%)
≥median	43 (50.59)
<median	42 (49.41)